The short answer
Review calcium intake as part of long-term primidone bone care. Extra calcium is not automatically needed, and a calcium-primidone spacing rule has not been established.
What this answer covers
Dietary or supplemental calcium during long-term oral primidone; not calcium-channel pharmacology or product excipients.
- Supplement or preparation
- Calcium
- Medication ingredient
- primidone
Why diet matters
Safety guidance identifies inadequate calcium intake as one risk factor for bone problems during long-term antiseizure treatment, including primidone. This is a reason to assess your intake.
Start with what you already consume
Describe calcium-containing foods and all supplements to your clinician. The goal is to identify a gap rather than automatically add another product.
Keep the evidence in perspective
A mixed-drug vitamin D trial does not prove that extra calcium benefits every primidone user. No validated interval for separating calcium from primidone was identified.
Keep the prescribed medicine steady
Do not stop primidone abruptly or adjust its dose to compensate for a supplement. Sudden withdrawal can provoke serious seizures. Tell the prescriber about new or worsening symptoms and all supplement changes.
Evidence and practical considerations
Timing & monitoring
Adequate calcium intake review is conditionally supported by exact named-drug bone guidance, not by evidence of a tablet-binding interaction.
- Exact scope
- Dietary or supplemental calcium during long-term oral primidone; not calcium-channel pharmacology or product excipients. with Exact oral primidone; parent and metabolites distinguished; no other drug/route assumed equivalent.
- Medication form and route
- oral supplement unless pregnancy section explicitly distinguishes neonatal injection
- Timing or duration
- Preparation, dose and duration determine applicability; chronic nutrition evidence is not a single-dose interaction.
What remains uncertain
- No isolated calcium intervention or exact absorption trial found. Vitamin D trial measured bone mineral content and cannot isolate calcium-supplement benefit.
Factors that may matter: exact supplement identity; dose; other medicines; clinical indication; baseline nutrition; pregnancy where relevant.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral primidone for epilepsy.
Primidone itself and its phenobarbital and PEMA metabolites have anticonvulsant activity. Drowsiness, ataxia and vertigo can occur. Rare megaloblastic anemia may respond to folic acid without stopping therapy. Label advises maternal vitamin K1 around delivery. Abrupt withdrawal can provoke status epilepticus.
How this applies: Exact RxCUI 8691 IN primidone, UNII 13AFD7670Q, oral tablets.
Parent and metabolites are distinct active exposures. Pregnancy label advice is not proof of benefit for routine prenatal vitamin K or a general adult supplement requirement.
Source 2: current product label
medicines.org.uk · Source check Sep 10, 2026
Population: Patients receiving oral primidone for epilepsy or essential tremor.
Potent CNS depressant; long-term vitamin D supplementation may be needed. Lists folates among co-treatments requiring attention; megaloblastic anemia can respond to folic acid/B12. St John’s wort is listed under contraindicated co-use because primidone concentrations and effectiveness may decrease. Maternal vitamin K1 is advised near delivery.
How this applies: Exact primidone label supports ingredient-specific boundaries rather than inference solely from phenobarbital metabolism.
Does not quantify botanical interactions or make parent and metabolite concentrations equivalent. Maternal vitamin K guidance differs from evidence reviews. No universal supplement spacing.
Source 3: official medication safety guidance
gov.uk · Source check Sep 10, 2026
Population: Patients receiving long-term antiseizure treatment, particularly those with nutritional or other bone risks.
Both named drugs are associated with osteomalacia. Vitamin D supplementation should be considered for at-risk long-term users; poor calcium intake, limited sunlight and immobility are risk factors.
How this applies: Exact named medications support conditional assessment of long-term bone and nutritional risk.
Guidance does not mean every user has a deficiency, requires the same dose, or benefits from a spacing interval. Older safety review, not a new randomized trial.
Source 4: original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 226 epilepsy outpatients treated with one or two drugs including phenobarbitone, primidone and phenytoin.
Average forearm bone mineral content increased during vitamin D2 treatment and remained unchanged in placebo/control groups.
How this applies: Apply only to the named drugs and study exposures; no unmeasured parent/metabolite or preparation equivalence.
Mixed medication population and surrogate outcome; abstract does not isolate exact-drug benefit, fracture prevention, D3 equivalence or an optimal current dose.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Exact current available claims reviewed against captured originals; no clinical review asserted. | |
| Research summary published |
Article revision: 1998655c0afdc2c4
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.